Eli Lilly Receives European Commission Approval for Kisunla in Early Alzheimer's Disease

Eli Lilly and Company today announced that the European Commission has approved Kisunla (donanemab) for the treatment of adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment or mild dementia stage of disease, with confirmed amyloid pathology. This approval makes Kisunla available to patients in all EU member states. The approval was based on the same pivotal TRAILBLAZER-ALZ 2 trial data that supported the FDA approval, demonstrating a 35% slowing of clinical decline compared to placebo. Lilly is committed to ensuring broad patient access to Kisunla across Europe.